Earlier this year, Eli Lilly sparked a lot of hope for donanemab by telling everybody the Trailblazer trial met its main goal. That goal was a significantly improved score on a relatively new test ...

Last year in March, Eli Lilly released the results of the TRAILBLAZER-ALZ 2 Phase 3 study of donanemab for Alzheimer's disease. Get stock picks, daily rankings, and pro-level trading tools in one ...

The FDA expects to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee to discuss Eli Lilly and Company’s (NYSE:LLY) Phase 3 TRAILBLAZER-ALZ 2 trial ...

The company said its Phase 3 Trailblazer-Alz2 study remains on track to read out in June. If the results are positive, Eli Lilly will apply for traditional approval. Unlike some previous FDA decisions ...

Last year in March, Eli Lilly released the results of the TRAILBLAZER-ALZ 2 Phase 3 study of donanemab for Alzheimer’s disease. Donanemab treatment slowed clinical decline by 35% compared to ...

Eli Lilly’s bid for an accelerated approval ... Donanemab is currently in a phase 3 trial called TRAILBLAZER-ALZ 2 that Lilly hopes will do just that. A top-line readout is expected in the ...

The US Food and Drug Administration declined to grant accelerated approval to an experimental Alzheimer’s drug, donanemab, and requested additional data from Eli Lilly and Company, the drug maker.

Eli Lilly has announced that its Alzheimer ... The pharmaceutical company on Wednesday shared the results from its TRAILBLAZER-ALZ2 Phase 3 clinical trial of donanemab for the treatment of ...